Last month, we sent information about some supply interruptions announced by Merck. Please see below for updates to the supply issues, which now include a pediatric vaccine:
- Adult formulation of Vaqta, a hepatitis A vaccine – anticipated return: Q3 2017
- Adult formulation of RecombivaxHB, a hepatitis B vaccine – anticipated return: Q3 2018
- Pediatric formulation of RecombivaxHB, a hepatitis B vaccine – anticipated return: Q1-Q2 2018
We understand that some wholesalers may have inventory on hand of pediatric RecombivaxHB; please consider reaching out to your supplier to inquire about availability.
Please note that these interruptions do not impact the supply of the pediatric formulation of Vaqta at this time.
During product shortages, CPP does not enforce program purchase guidelines for the affected vaccines. To stay up to date on product availability, refer to the Merck Vaccines Supply Status website.